Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Raised to Buy at Deutsche Bank Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating in a report issued on Thursday.

A number of other equities research analysts have also commented on BAYRY. Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Zacks Research upgraded Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday, May 8th. UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Finally, DZ Bank upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Price Performance

OTCMKTS BAYRY opened at $13.85 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.70 and a current ratio of 1.05. The stock has a market cap of $54.43 billion, a price-to-earnings ratio of -21.64, a PEG ratio of 4.37 and a beta of 0.54. The business has a 50 day simple moving average of $11.06 and a 200 day simple moving average of $11.57. Bayer Aktiengesellschaft has a 52-week low of $7.19 and a 52-week high of $14.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.15. The firm had revenue of $15.73 billion for the quarter, compared to analyst estimates of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Analysts anticipate that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.